vs
Molecular weight
4113.58 g/mol
4813.45 g/mol
Half-life
~7 days (168 hours)
~5 days (120 hours)
Research areas
Weight loss / obesityType 2 diabetesCardiovascular risk reductionNASH / MASH (fatty liver)Chronic kidney diseaseAlcohol use disorder
Weight loss / obesityType 2 diabetesMetabolic syndromeObstructive sleep apneaHeart failure with preserved ejection fraction (HFpEF)NASH / MASH
Typical dosing
250–2400 mcg · 1x weekly · Ongoing (titrate up over 16-20 weeks)
2500–15000 mcg · 1x weekly · Ongoing (titrate over 20+ weeks)
FDA status
FDA-approved (Ozempic for T2D 2017, Wegovy for weight management 2021, Rybelsus oral for T2D 2019)
FDA-approved (Mounjaro for T2D Nov 2022, Zepbound for weight management Nov 2023)
WADA status
Not prohibited (as of 2026)
Not prohibited (as of 2026)
